GILD Gilead Corp: Earnings per share for the trailing year

Measuring the annual EPS TTM growth confirms the status of Gilead Sciences, Inc. (GILD) as an absolute authority in the fight against viruses. The value -147.50 denotes the current profit growth metric. Gilead Sciences, Inc. (GILD) possesses a closed system of HIV and hepatitis therapies that creates high patient loyalty. Further development is based on expansion into immunology and oncology, as well as the implementation of long-term treatment regimens.
gilead.com - analytical breakdowns and key metrics (GILD)

Portfolio managers evaluate the operating model of Gilead Sciences, Inc. (GILD) based on profit generation rates. This indicator measures the annual change in net income per share over the last 12 months, reacting in real-time to 10-K and 10-Q reports. The current value of -147.50 in the history of annual EPS TTM dynamics reflects the efficiency of the expansion into oncology and infection therapy. The positive trend confirms the resilience of the business diversification.